Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.10.2012 | Brief Report

Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors

verfasst von: Laura A. Petrillo, Denise M. Wolf, Ann M. Kapoun, Nicholas J. Wang, Andrea Barczak, Yuanyuan Xiao, Hasan Korkaya, Frederick Baehner, John Lewicki, Max Wicha, John W. Park, Paul T. Spellman, Joe W. Gray, Laura van’t Veer, Laura J. Esserman

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Though xenografts are used extensively for drug development in breast cancer, how well xenografts reflect the breadth of primary breast tumor subtypes has not been well characterized. Moreover, few studies have compared the gene expression of xenograft tumors to the primary tumors from which they were derived. Here we investigate whether the ability of human breast tumors (n = 20) to create xenografts in immune-deficient mice is associated with breast cancer immunohistochemical (IHC) and intrinsic subtype. We also characterize how precisely the gene expression of xenografts reprises that of parent breast tumors, using hierarchical clustering and other correlation-based techniques applied to Agilent 44K gene expression data from 16 samples including four matched primary tumor-xenograft pairs. Of the breast tumors studied, 25 % (5/20) generated xenografts. Receptor and intrinsic subtype were significant predictors of xenograft success, with all (4/4) triple-negative (TN) tumors and no (0/12) HR+Her2− tumors forming xenografts (P = 0.0005). Tumor cell expression of ALDH1, a stem cell marker, trended toward successful engraftment (P = 0.14), though CDK5/6, a basal marker, did not. Though hierarchical clustering across the 500 most variable genes segregated human breast tumors from xenograft tumors, when clustering was performed over the PAM50 gene set the primary tumor-xenograft pairs clustered together, with all IHC subtypes clustered in distinct groups. Greater similarity between primary tumor-xenograft pairs relative to random pairings was confirmed by calculation of the within-pair between-pair scatter ratio (WPBPSR) distribution (P = 0.0269), though there was a shift in the xenografts toward more aggressive features including higher proliferation scores relative to the primary. Triple-negative breast tumors demonstrate superior ability to create xenografts compared to HR+ tumors, which may reflect higher proliferation or relatively stroma-independent growth of this subtype. Xenograft tumors’ gene expression faithfully resembles that of their parent tumors, yet also demonstrates a shift toward more aggressive molecular features.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Giovanella B, Stehlin J, Williams L, Shih-Shun L, Shepard R (1978) Heterotransplantation of human cancers into nude mice. Cancer 42:2269–2281PubMedCrossRef Giovanella B, Stehlin J, Williams L, Shih-Shun L, Shepard R (1978) Heterotransplantation of human cancers into nude mice. Cancer 42:2269–2281PubMedCrossRef
2.
Zurück zum Zitat Steel GG, Courtenay VD, Peckham MJ (1983) The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 47:001–013CrossRef Steel GG, Courtenay VD, Peckham MJ (1983) The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 47:001–013CrossRef
3.
Zurück zum Zitat Rae-Venter B, Reid LM (1980) Growth of human breast carcinomas in nude mice and subsequent establishment in tissue culture. Cancer Res 40:95–100PubMed Rae-Venter B, Reid LM (1980) Growth of human breast carcinomas in nude mice and subsequent establishment in tissue culture. Cancer Res 40:95–100PubMed
4.
Zurück zum Zitat Mehta R, Graves J, Hart G, Shilkaitis A, Das Gupta T (1993) Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res Treat 25:65–71PubMedCrossRef Mehta R, Graves J, Hart G, Shilkaitis A, Das Gupta T (1993) Growth and metastasis of human breast carcinomas with Matrigel in athymic mice. Breast Cancer Res Treat 25:65–71PubMedCrossRef
5.
Zurück zum Zitat Clarke R (1996) Human breast cancer cell line xenografts as models of breast cancer—the immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39:69–86PubMedCrossRef Clarke R (1996) Human breast cancer cell line xenografts as models of breast cancer—the immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39:69–86PubMedCrossRef
6.
Zurück zum Zitat Pegram M, Ngo D (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): a case study. Adv Drug Deliv Rev 58(5–6):723–734PubMedCrossRef Pegram M, Ngo D (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): a case study. Adv Drug Deliv Rev 58(5–6):723–734PubMedCrossRef
7.
Zurück zum Zitat Keller PJ et al (2010) Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 12(5):R87PubMedCrossRef Keller PJ et al (2010) Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 12(5):R87PubMedCrossRef
8.
Zurück zum Zitat Reyal F et al (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14(1):R11PubMedCrossRef Reyal F et al (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14(1):R11PubMedCrossRef
9.
Zurück zum Zitat Valdez KE et al (2011) Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol 225(4):565–573PubMedCrossRef Valdez KE et al (2011) Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model. J Pathol 225(4):565–573PubMedCrossRef
10.
Zurück zum Zitat Moestue SA et al (2010) Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 10:433PubMedCrossRef Moestue SA et al (2010) Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 10:433PubMedCrossRef
11.
Zurück zum Zitat Bergamaschi A et al (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3(5–6):469–482PubMedCrossRef Bergamaschi A et al (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3(5–6):469–482PubMedCrossRef
12.
Zurück zum Zitat Ding L et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999–1005PubMedCrossRef Ding L et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999–1005PubMedCrossRef
13.
Zurück zum Zitat Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. N Engl J Med 363(20):1938–1948PubMedCrossRef Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. N Engl J Med 363(20):1938–1948PubMedCrossRef
14.
Zurück zum Zitat Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
15.
Zurück zum Zitat Resetkova E, Reis-Filho J, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S (2010) Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 123(1):97–108PubMedCrossRef Resetkova E, Reis-Filho J, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S (2010) Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 123(1):97–108PubMedCrossRef
16.
Zurück zum Zitat Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567PubMedCrossRef Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567PubMedCrossRef
17.
Zurück zum Zitat Dalerba P, Dylla SJ, Park I, Liu R, Wang X, Cho R, Hoey T, Gurney A, Huang E, Simeone D, Shelton A, Parmiani G, Castelli C, Clarke M (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci 104(24):10158–10163PubMedCrossRef Dalerba P, Dylla SJ, Park I, Liu R, Wang X, Cho R, Hoey T, Gurney A, Huang E, Simeone D, Shelton A, Parmiani G, Castelli C, Clarke M (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci 104(24):10158–10163PubMedCrossRef
18.
Zurück zum Zitat Bolstad BM et al (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2):185–193PubMedCrossRef Bolstad BM et al (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2):185–193PubMedCrossRef
19.
Zurück zum Zitat Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R et al (eds) Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R et al (eds) Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York
20.
Zurück zum Zitat Parker JS, Michael M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167PubMedCrossRef Parker JS, Michael M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167PubMedCrossRef
21.
Zurück zum Zitat Seber GAF (1984) Multivariate observations. John Wiley & Sons, Hoboken, NJCrossRef Seber GAF (1984) Multivariate observations. John Wiley & Sons, Hoboken, NJCrossRef
22.
Zurück zum Zitat Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van’t Veer LJ (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65(20):9155–9158PubMedCrossRef Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM, Van’t Veer LJ (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65(20):9155–9158PubMedCrossRef
23.
Zurück zum Zitat Lonnstedt I, Speed T (2002) Replicated microarray data. Stat Sin 12(1):31–46 Lonnstedt I, Speed T (2002) Replicated microarray data. Stat Sin 12(1):31–46
24.
Zurück zum Zitat Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocol 4(1):44–57CrossRef Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocol 4(1):44–57CrossRef
25.
Zurück zum Zitat Marangoni E et al (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989–3998PubMedCrossRef Marangoni E et al (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989–3998PubMedCrossRef
26.
Zurück zum Zitat de Plater L et al (2010) Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 103(8):1192–1200PubMedCrossRef de Plater L et al (2010) Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 103(8):1192–1200PubMedCrossRef
Metadaten
Titel
Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors
verfasst von
Laura A. Petrillo
Denise M. Wolf
Ann M. Kapoun
Nicholas J. Wang
Andrea Barczak
Yuanyuan Xiao
Hasan Korkaya
Frederick Baehner
John Lewicki
Max Wicha
John W. Park
Paul T. Spellman
Joe W. Gray
Laura van’t Veer
Laura J. Esserman
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2226-y

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.